Coherus appoints Michael Ryan to board of directors

Coherus Oncology, Inc.

Michael Ryan appointed to Coherus board effective July 18, 2023; fills Class III vacancy until 2026 annual meeting.
Ryan has 40 years in biopharma; most recently SVP at Bristol-Myers Squibb and earlier VP at Amgen.
Compensation: annual cash retainer of $50,000; initial option for 54,000 shares vesting monthly over 3 years.
Also founder/CEO of Koios Enterprises, an executive consulting firm focusing on patient access.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Ryan

Class III director

CHRS · Coherus Oncology, Inc.

Effective: 2023-07-18
Filed: July 20, 2023, 7:59 PM ET

On July 18, 2023, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Michael Ryan, Pharm.D., to serve as a Class III director to fill a vacancy on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Ryan was appointed as Class III director at Coherus Oncology, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On July 18, 2023, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Michael Ryan, Pharm.D., to serve as a Class III director to fill a vacancy on the Board.

View on SEC.gov

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-012028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.